Pfizer Inc.’s Covid-19 pill received backing from the European Union’s drugs regulator, offering a tool to manage coronavirus infections at home and ease the burden on hospitals.
The European Medicines Agency’s expert committee recommended granting conditional marketing authorization for the antiviral, called Paxlovid, for adults with Covid who don’t require supplemental oxygen and are at risk of developing severe disease, the regulator said Thursday.
